GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Colorectal Cancer

Colorectal cancer stage III Who May Qualify: - Colorectal cancer, UICC stage III - Has received curative-intent resection and is a candidate for adjuvant chemotherapy - Patient able to understand and sign written willing to sign a consent form Who Should NOT Join This Trial: - Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome - Inflammatory bowel disease (Crohn's disease or ulcerative colitis) - Verified distant metastases - Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included) - Treated with neoadjuvant chemo-radiation therapy - No tissue sample available for the project, or tumor content in the tissue sample is \<20% - Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) - Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening - Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study Colorectal cancer liver metastasis Who May Qualify: - Colorectal cancer liver metastasis - Planned for curative-intent treatment - Performance status 0-1 Who Should NOT Join This Trial: - Liver cirrhosis - Extrahepatic metastases - Other cancer within the last 5 years - Intervention not performed with curative intent - No tissue available from CRLM or primary tumor Always talk to your doctor about whether this trial is right for you.